Delving into the Latest Updates on Aprogen Biologics, Inc. with Synapse

Overview

Tags

Immune System Diseases

Skin and Musculoskeletal Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

The aim of this study was to determine the potential for an additive effect from combining treatments with tolerogenic dendritic cells (tDCs) and etanercept (ETN) in a case of established type II collagen-induced arthritis (CIA).CIA mice were treated with type II collagen-pulsed tDCs either alone or in combination with ETN.We compared the effects of monotherapy with tDCs or ETN with the effect of combination treatment on the resultant rheumatoid arthritis using histopathol. analyzes and measurements of paw volumes, regulatory T cell populations, and cytokine levels.The clin. and histol. anal. revealed an additive effect from the combination therapy.Monotherapy with tDCs showed a tendency to ameliorate arthritis symptoms, while monotherapy with ETN reduced the paw swelling at 3 days after administration, but was not effective toward the end of the exptl. period.The combined treatment group also showed a marked inducement of the regulatory T cells and Th2 cytokines that are affected by tDCs compared with those of either untreated or ETN-treated CIA mice.ETN administered in combination with tDCs provided a substantially higher level of clin. benefit at the cellular level to CIA mice than the administration of either of these agents alone.

100 Deals associated with Aprogen Biologics, Inc.

Login to view more data

100 Translational Medicine associated with Aprogen Biologics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data